BTK Inhibitor drugs such as Ibrutinib, Zanubrutinib, etc, are very good drugs for the treatment of WM, especially for relapsed and refractory WM. Unfortunately, unlike other drugs used in the treatment of WM, they are currently not generally funded by the Provinces for the treatment of WM, primarily because of their high cost. This is despite the fact that most of these drugs are approved by Health Canada for the treatment of WM.
So, unlike other drugs used in the treatment of WM, paying for these drugs becomes an issue.
We have addressed the question of “How does one manage the costs of BTK Inhibitors?” in a new question added to our Common Canadian Questions Answered page.